LKB1, a tumor-suppressor gene that codifies for a serine/ threonine kinase, is mutated in the germ-line of patients affected with the Peutz-Jeghers syndrome (PJS), which have an increased incidence of several cancers including gastrointestinal, pancreatic and lung carcinomas. Regarding tumors arising in non-PJS patients, we recently observed that at least one-third of lung adenocarcinomas (LADs) harbor somatic LKB1 gene mutations, supporting a role for LKB1 in the origin of some sporadic tumors. To characterize the pattern of LKB1 mutations in LADs further, we first screened for LKB1 gene alterations (gene mutations, promoter hypermethylation and homozygous deletions) in 19 LADs and, in agreement with our previous data, five of them (26%) were shown to harbor mutations, all of which gave rise to a truncated protein. Recent reports demonstrate that LKB1 is able to suppress cell growth, but little is known about the specific mechanism by which it functions. To further our understanding of LKB1 function, we analysed global expression in lung primary tumors using cDNA microarrays to identify LKB1-specific variations in gene expression. In all, 34 transcripts, 24 of which corresponded to known genes, differed significantly between tumors with and without LKB1 gene alterations. Among the most remarkable findings was deregulation of transcripts involved in signal transduction (e.g. FRAP1/mTOR, ARAF1 and ROCK2), cytoskeleton (e.g. MPP1), transcription factors (e.g. MEIS2, ATF5), metabolism of AMP (AMPD3 and APRT) and ubiquitinization (e.g. USP16 and UBE2L3). Real-time quantitative RT-PCR on 15 tumors confirmed the upregulation of the homeobox MEIS2 and of the AMP-metabolism AMPD3 transcripts in LKB1-mutant tumors. In addition, immunohistochemistry in 10 of the lung tumors showed the absence of phosphorylated FRAP1/mTOR protein in LKB1-mutant tumors, indicating that LKB1 mutations do not lead to FRAP1/mTOR protein kinase activation. In conclusion, our results reveal that several important factors contribute to LKB1-mediated carcinogenesis in LADs, confirming previous observations and identifying new putative pathways that should help to elucidate the biological role of LKB1.
LKB1, a tumor-suppressor gene that codifies for a serine/ threonine kinase, is mutated in the germ-line of patients affected with the Peutz-Jeghers syndrome (PJS), which have an increased incidence of several cancers including gastrointestinal, pancreatic and lung carcinomas. Regarding tumors arising in non-PJS patients, we recently observed that at least one-third of lung adenocarcinomas (LADs) harbor somatic LKB1 gene mutations, supporting a role for LKB1 in the origin of some sporadic tumors. To characterize the pattern of LKB1 mutations in LADs further, we first screened for LKB1 gene alterations (gene mutations, promoter hypermethylation and homozygous deletions) in 19 LADs and, in agreement with our previous data, five of them (26%) were shown to harbor mutations, all of which gave rise to a truncated protein. Recent reports demonstrate that LKB1 is able to suppress cell growth, but little is known about the specific mechanism by which it functions. To further our understanding of LKB1 function, we analysed global expression in lung primary tumors using cDNA microarrays to identify LKB1-specific variations in gene expression. In all, 34 transcripts, 24 of which corresponded to known genes, differed significantly between tumors with and without LKB1 gene alterations. Among the most remarkable findings was deregulation of transcripts involved in signal transduction (e.g. FRAP1/mTOR, ARAF1 and ROCK2), cytoskeleton (e.g. MPP1), transcription factors (e.g. MEIS2, ATF5), metabolism of AMP (AMPD3 and APRT) and ubiquitinization (e.g. USP16 and UBE2L3). Real-time quantitative RT-PCR on 15 tumors confirmed the upregulation of the homeobox MEIS2 and of the AMP-metabolism AMPD3 transcripts in LKB1-mutant tumors. In addition, immunohistochemistry in 10 of the lung tumors showed the absence of phosphorylated FRAP1/mTOR protein in LKB1-mutant tumors, indicating that LKB1 mutations do not lead to FRAP1/mTOR Introduction Germ-line mutations of the LKB1 gene, also named STK11, cause Peutz-Jeghers syndrome (PJS) (Hemminki et al., 1998; Jenne et al., 1998) , an autosomal dominant genetic disorder that predisposes to a wide variety of malignancies predominantly of the gastrointestinal tract and also the genitourinary tract, breast and lung (Jeghers et al., 1949; Giardiello et al., 1987) . We recently detected somatic LKB1 gene-inactivating mutations in one-third of sporadic lung adenocarcinomas (LADs) and in half of lung cancer cell lines of the LAD histological type, indicating that LKB1 plays a relevant role in an extremely frequent cancer type such as is that of the lung (Sanchez-Cespedes et al., 2002; Carretero et al., 2004) .
The LKB1 protein is a serine/threonine kinase. Closely related orthologues of LKB1 have been found in mouse (Lkb1), Xenopus (Xeek1), Drosophila and Caenorhabditis elegans (Par4) (Su et al., 1996; Smith et al., 1999; Watts et al., 2000; Martin and St Johnson, 2003) . Lkb1 orthologues in Xenopus and C. elegans are involved in early embryonic development (Su et al., 1996; Watts et al., 2000) and the Lkb1-homologue in Drosophila is required for early anterior-posterior axis formation and epithelial polarity (Martin and St Johnson, 2003) . The relevance of Lkb1 in early mammalian development has been demonstrated further by the use of Lkb1-deficient mice (Lkb1
), which die early in gestation due to severe neural-tube defects and numerous vascular abnormalities (Ylikorkala et al., 2001) . These observations are consistent with the global expression profile of embryonic fibroblasts from Lkb1 À/À mice, which have abnormal expression levels of factors associated with angiogenesis, extracellular remodeling, cell adhesion and inhibition of ras transformation (Bardeesy et al., 2002) . Taken together, these results herald an essential role of LKB1 during normal embryonic development. Interestingly, Lkb1-heterozygous mice (Lkb1 þ /À ) are viable and mimic the cancer predisposition phenotype of PJS, developing multiple gastrointestinal hamartomatous polyps and various tumors such as hepatocellular carcinomas Nakau et al., 2002) .
Human LKB1 encodes a 436-amino-acid protein with a kinase domain (residues 50-319), similar to the SNF1/ AMP-activated protein kinase family, and a putative carboxyl-terminal regulatory domain with a CAAXbox, a consensus sequence for prenylation. Two potential nuclear localization signals are located between amino acids 38-43 and 81-84 (see reference Yoo et al., 2002 , for a review). LKB1 protein has been detected in both the cytoplasm and nucleus of endogenous and transfected cells (Nezu et al., 1999; Collins et al., 2000; Karuman et al., 2001) . LKB1-mutant protein devoid of nuclear localization signal still has the ability to inhibit cell growth, suggesting that LKB1 cytoplasm retention may be critical for its tumorsuppression function (Tiainen et al., 2002) . Several proteins such as p53, BRG1 and LIP1 (Karuman et al., 2001; Marignani et al., 2001; Smith et al., 2001) are thought to bind LKB1. LKB1 has been implicated in different pathways such as p53-dependent apoptosis, p21-mediated cell growth arrest, VEGF-signaling pathway and ATM response to ionizing radiation (Tiainen et al., 1999; Karuman et al., 2001; Bardeesy et al., 2002; Sapkota et al., 2002) . Moreover, LKB1 activity may be regulated by p90RSK phosphorylation and there is also evidence that LKB1 physiologically interacts with the kinase-specific chaperone heterodimer CdC37 and Hsp90, thereby playing a role in regulating the cellular stability of LKB1 (Sapkota et al., 2001) .
We have recently shown that overexpression of ectopic wild-type-LKB1 protein triggers cell growth suppression in the A549 LAD cell line. In addition, analysis of global expression patterns in A549 cells following LKB1 ectopic expression revealed the deregulation of transcripts involved in apoptosis, cell adhesion and signal transduction, including several members of the PTEN/PI3K/AKT pathway (Jimenez et al., 2003) .
To investigate the role of LKB1 in lung cancer further, we looked for LKB1 gene inactivation in primary LADs and segregated them according to the presence or absence of LKB1 gene mutations. Global expression profiling was performed using cDNA microarrays to identify those genes whose expression patterns significantly varied between lung tumors with and without LKB1 mutations. Our observations can help to unravel the biological function and to identify the upstream/downstream targets of the LKB1 protein.
Results

Characteristics of LKB1 gene alterations in LADs
LKB1 gene somatic mutations were detected in five out of 19 primary tumors (26%). Interestingly, and in agreement with our previous observations (SanchezCespedes et al., 2002; Carretero et al., 2004) , all mutations generated a truncated or incomplete LKB1 protein. The mutations detected were a Tyr to Stop at codon 60 (tumor 158), Glu to Stop at codon 120 (tumor 129), G insertion at codon 279 (tumor 136), Glu to Stop at codon 65 (tumor 272) and a complete deletion of exon 8 (tumor 227) that abrogates part of the kinase domain of the protein (Figure 1a and b) ( Table 1 ). The homozygous nature of all mutations in the primary tumors was confirmed by FISH analysis. As detailed in the methodology section, a tumor was considered positive for LOH at the LKB1 locus (located at the short arm of chromosome 19, 19p13. 3) when more than 35% of the cells showed a single signal for the LKB1 probe and two control signals coming from the normal copies of the long arm of chromosome 19. According to this definition, 10 of the 18 tumors available for FISH analysis (55%) carried LOH at this locus. We also detected one tumor carrying 6-8-fold amplification at the LKB1 gene. No homozygous deletions spanning LKB1 gene, or gene promoter hypermethylation were detected in any of the tumors analysed, according to our data based on FISH analysis and MSP, respectively. Table 1 lists all LKB1 gene alterations that we have found to date in primary LADs. As can be seen, mutations are scattered throughout almost the entire coding region of LKB1 gene. However, mutations in the first two exons account for almost half of the tumors, whereas no alterations were detected in exon 9. In addition, of the LADs carrying LKB1 mutations, simultaneous KRAS and p53 mutations occurred in four (36%) and six (54%) of the tumors, respectively (Table 1) .
Differences in gene expression depending on the presence or absence of LKB1 mutations
To determine the global expression profile in our set of lung tumors, we used 30-35 mg of total RNA extracted from 19 primary tumors and equal amounts of reference RNA. cDNA from lung tumors and from the reference pool were labeled with Cy5 (red) and Cy3 (green), respectively, and applied in competitive hybridization on the CNIO OncoChip v.1.1c microarray (see Materials and methods section). Fluorescence-intensity ratios were calculated and gene-expression profiles were generated for each sample. To assess interexperimental variability and thus, the reproducibility of the results, this assay was repeated for one of the primary tumors (no. 227). A reliable and reproducible result was obtained in two independent hybridizations (correlation coefficient r ¼ 0.75) (Figure 2a ). To identify genes whose expression level may be linked to the LKB1 gene status, we determined the distinctive patterns of gene expression in tumors with and without LKB1 gene alterations. Our statistical analysis (see Materials and methods section) revealed that 34 transcripts, including 24 known genes, were differentially expressed in the five tumors carrying LKB1 gene mutations, compared with the 14 remaining tumors. Overall, our results showed that 11 and 13 of the known genes were up and downregulated, respectively, in LKB1-mutation-positive tumors relative to their expression in LKB1-mutation-negative tumors ( Figure 2b ). Figure 2b also depicts all genes differentially expressed in the two groups of tumors. The Pvalues (Po0.01) are indicated in each case. Examination of individual genes from the list reveals that many of them belong to signal transduction pathways, such as ARAF1 and FRAP1/mTOR, implicated in the signaling through KRAS and PTEN/PI3 K, respectively. Other common deregulated cell processes were cell adhesion/ cell structure (MPP1, FAT2), transcription factors (MEIS2, ATF5, PLAGL1), ubiquitinization (e.g. We verified the relative expression of two of these 24 genes by real-time (TaqMan) quantitative RT-PCR in 15 of the tumors (five LKB1-mutant and 10 LKB1-wild type). The selected genes were MEIS2 and AMPD3. As a control gene, we used the TATA-binding protein (TBP). In Figure 2c , it is shown the DCt difference and the fold change in gene expression are relative to the LKB1-wild-type group. Both genes demonstrated consistent upregulation in LKB1-mutant tumors in agreement with the cDNA microarray observations. One of the downregulated transcripts detected in our cDNA microarray analysis was FRAP1/mTOR, an important mediator of the PI3K/PTEN pathway. To further understand whether downregulation of FRAP1/ mTOR transcript correlated with decreased levels of active (phosphorylated) FRAP1/mTOR protein, we performed immunohistochemistry using antibodies against the phosphorylated form of FRAP1/mTOR in Expression profile of LKB1 mutant tumors P Fernandez et al 10 of the lung primary tumors with available paraffinembedded tissue (two LKB1-mutant and eight LKB1-wild-type tumors). Following previously published criteria, levels of phosphorylated and active FRAP1/ mTOR protein were categorized as 0, absence; 1, medium to low; and 2, high levels of protein expression (Choe et al., 2003) . Immunoreactivity for the active form of the FRAP1/mTOR protein was observed in the cytoplasm. Representative examples of the immunostaining are shown in Figure 2d . The two LKB1-mutant tumors available for the analysis had absence of activated FRAP1/mTOR protein, in agreement with the strong downregulation of the transcript observed in the microarrays-based data. On the other hand, among the LKB1-wild-type tumors five carried moderate-to-high levels and three had no detectable expression of activated FRAP1/mTOR protein, in complete concordance with the cDNA microarray observations.
Discussion
The importance of LKB1 gene in the development of lung cancer is strongly supported by the common presence of inactivating mutations (Sanchez-Cespedes et al., 2002; Carretero et al., 2004) . One-third of primary LADs harbored mutations at the LKB1 gene, but this percentage could be underestimated in primary tumors, most likely because the masking effect of contaminant normal cells makes it difficult to detect large deletions and complex gene rearrangements. Thus, the complete exon 8-deletion in the 227-SP primary tumor would have been masked if long-range PCR had not been carried out. The summary of all LKB1 gene alterations in lung tumors reveals a remarkable predominance of nonsense/frameshift mutations (only one missense mutation in a primary LAD had previously been reported) (Avizienyte et al., 1999) , which tend to accumulate in the first half of the gene. This mutational pattern is similar to that found in the PJS patients whose LKB1 mutations are mainly of the frameshift or nonsense type, giving rise to truncated proteins (Hemminki et al., 1998; Jenne et al., 1998) . Together, these observations imply that complete abrogation of the LKB1 protein function is required for LKB1-driven carcinogenesis.
In spite of the important tumor-suppressor role of LKB1 gene in the Peutz-Jeghers syndrome and in sporadic LADs, its biological function is still not fully understood. Several studies have demonstrated that ectopic LKB1 can suppress the growth of LKB1-defficient tumor cells (Tiainen et al., 1999; Karuman et al., 2001; Marignani et al., 2001; Jimenez et al., 2003) . Such growth suppression may arise through cell cycle arrest at G1/S, mediated by p21 (Tiainen et al., 1999) , through p53-mediated apoptosis (Karuman et al., 2001) or both. However, the coexistence of KRAS and p53 mutations with LKB1 mutations in several lung (Sanchez-Cespedes et al., 2002) and pancreatic (Su et al., 1999) tumors suggests that LKB1 functions in a molecular pathway different from that of p53 or KRAS, and so cooperates during the carcinogenetic process of LADs.
To obtain further insights into the biological role of LKB1, we looked for genes that are differentially expressed in LADs with and without LKB1 gene alterations. We previously demonstrated that ectopic wild-type LKB1 protein in A549 lung cancer cells leads to changes in the expression of more than 100 transcripts, many of them involved in cell proliferation, apoptosis and cytoskeleton/cell adhesion (Jimenez et al., 2003) . Overall, our current results share similarities to our previous observations. It is of particular note that LKB1-mutation-positive tumors show significantly different levels of expression of genes involved in signal transduction pathways such as FRAP1/mTOR and ARAF1 compared with those in LKB1-mutationnegative tumors. Indeed, FRAP1/mTOR belongs to the PI3K/PTEN signal transduction pathway, which also turned out to be deregulated following ectopic expression of wild-type LKB1 in A549 cells (Jimenez et al., 2003) . Given the similarity between Cowden's disease (Hanssen and Fryns, 1995) caused by PTEN germ-line mutations and the PJS, it has been postulated that PTEN and LKB1 may act in a common biochemical pathway (Yoo et al., 2002) . However, others have not found alterations in PTEN or AKT-P protein levels when comparing cells harboring wild-type or mutant LKB1 (Rossi et al., 2002) . Our present observations indicate that activation of the FRAP1/mTOR protein kinase is important during lung carcinogenesis of most LKB1-wild type but not LKB1-mutant tumors. Whereas the possible connexion between the PI3K/PTEN and LKB1 pathways remains to be clarified, our data may help to discriminate those lung cancer patients resistant to rapamycin or to other mTOR inhibitors, currently being developed by several pharmaceutical and biotechnology companies.
Interestingly, recent reports demonstrate that LKB1 is the upstream regulator of the AMPK protein (AMPactivated protein kinase), together with its binding partners MO25 and STRAD Hawley et al., 2003) . The AMPK is a sensor of cellular energy and is activated by the increase of the 5 0 -AMP levels, which accompanies a fall in the ATP : ADP ratio (Kemp et al., 1999) . In addition to acting as a key regulator of cell metabolism, active AMPK also inhibits cell proliferation (Kemp et al., 1999) . Interestingly, we observed that LKB1-mutant tumors undergo upregulation of the AMPD3 transcript, involved in the metabolism of the AMP, which may be related to the lack of AMPK activation in these subsets of lung tumors.
There were other remarkable differences in gene expression such as MEIS2 (myeloid ecotropic viral integration site 1 homologue 2), a transcript upregulated in lung tumors carrying LKB1 mutations. This gene encodes a homeobox of the TALE family of proteins, which are highly conserved transcription regulators, essential during development (Zhang et al., 2002) and highly overexpressed in some tumor types such as neuroblastoma (Geerts et al., 2003) .
In summary, the biological and functional profile of LKB1 mutant tumors is strongly characterized by an overactivation of signal transduction pathways, deregulation of the levels of adhesion molecules that may promote cell invasion and migration and altered levels of transcripts involved in various cell functions, including transcriptional regulation, metabolism and ubiquitinization.
Materials and methods
Patient selection and DNA extraction
Tumor and matched normal tissues from 19 patients diagnosed with lung cancer were provided by the CNIO Tumor Bank Network, CNIO (Madrid, Spain), with the collaboration of the following hospitals: Hospital Universitario 12 de Octubre and Hospital Puerta de Hierro in Madrid and Hospital Virgen de la Salud, in Toledo. Cases were selected on the basis of the availability of frozen tissue and were uniformly reviewed and classified as adenocarcinomas.
Representative sections from tissue used for DNA extraction were stained with H&E. Freshly frozen tissue from tumors was meticulously dissected to ensure that specimens contained al least 75% tumor cells. Approximately 10-20 mm sections were collected from normal and tumor samples and placed in 1% SDS/proteinase K (10 mg/ml) at 581C overnight. Digested tissue was then subjected to phenol-chloroform extraction and ethanol precipitation.
Screening for mutations, deletions and promoter hypermethylation
In all, 100 ng of genomic DNA were used for exon amplification. Cycle-sequencing reaction was performed according to the manufacturer's protocol (Perkin-Elmer, Roche Molecular System). Sequencing conditions for LKB1 were: 951C 30 s, 561C 1 min and 721C 1 min for one cycle; and 951C 30 s, 531C 1 min and 721C 1 min for 34 cycles. Sequencing products were separated by electrophoresis through 6% polyacrylamide gels and exposed to a film for 24-48 h. Primers and specific conditions used for the screening of LKB1-point mutations have been described previously (Sanchez-Cespedes et al., 2002) . Screening of KRAS mutations at codons 12 and 13 was performed in tumor DNA using a highly sensitive PCR-RFLP assay (Schimanski et al., 1999) . Mutant bands in the agarose gel were excised, purified (Ultraclean 15 Kit, MOBIO laboratories, CA, USA) and automatically sequenced on an ABI PRISM 3700 DNA Analyser (PE Biosystems). Point mutations at p53, codons 5-9 were analysed by PCR amplification of a 1800-bp fragment containing codons 5-9: primer forward 5 0 -GCTTTATCTGTTCACTTGTG-3 0 and reverse 5 0 -CTACAACCAGGAGCCATTGTC-3 0 followed by automatic sequencing of individual exons.
To screen for deletions in the vicinity of exons 2-8, we used a long-range PCR strategy, as described previously (SanchezCespedes et al., 2002) . Briefly, we amplified a 5-Kb fragment containing exons from 2 to 8 of the LKB1 gene using Elongase Enzyme Mix (Invitrogen). PCR products were loaded in 0.7-1% agarose gels. To ensure that all LKB1 mutations were homozygous (loss of heterozygosity) and to detect the presence of homozygous deletions, we performed FISH analysis on frozen samples of the tumors. We used three cosmid clones: LLNLR-252D12, 264D11 and 277D11, from the LLNL Human Chromosome library (MRC UK HGMP Resource Centre, Babraham, Cambridge, UK). These clones covered the LKB1 and the adjacent genomic area. For the deletion analysis, we used a control probe composed of two overlapping bacterial artificial chromosomes (BAC) that map to the long arm of chromosome 19. The three cosmid clones were pooled and labeled by nick translation with Spectrum Green (Vysis, Downer's Grove, IL, USA). The control clones were pooled and identically labeled with Spectrum Orange (Vysis, Downer's Grove, IL, USA). The frozen tissue was fixed onto the slides with 100% ethanol. The slides were boiled in a pressure cooker with 1 mM EDTA, pH 8.0 for 2 min, and incubated with pepsin at 371C for 30 min. The slides were then dehydrated. The samples and probes were codenatured at 751C for 2 min, then placed overnight for hybridization at 371C in a humid chamber. Slides were washed with 0.4 X SSC and 0.3% NP40.
The FISH analysis was performed by two investigators (SR and JCC) with no previous knowledge of the genetic or clinical nature of the samples. Scoring of fluorescence signals was made in each sample by counting the number of single copy gene and control probe signals in an average of 180 (163-215) well-defined nuclei. The cut-off value for deletions was established as the mean plus three times the standard deviation of the proportion of cells with one signal in the three normal nontumoral samples. This value corresponded to 35% of cells. Tumor samples with 435% of cells with one signal were considered to be subject to genomic loss involving the LKB1 genomic region.
Hypermethylation at LKB1 gene promoter was assessed by MSP (methylation-specific PCR) as previously described (Esteller et al., 2000) .
cDNA microarray analysis
Total RNA extraction was carried out using the Trizol reagent (Life Technologies, Inc., Grand Island, NY, USA), RNeasy kit (Qiagen Inc., Valencia, CA, USA) and digested with RNasefree DNase I following the manufacturer's instructions. A small aliquot of RNA was separated for quantification and for quality control.
In all, 40 mg of total RNA was used for cDNA microarrays analysis. Fluorescent-labeled cDNA was synthesized and hybridized to the CNIO OncoChip, as previously described (Tracey et al., 2002) . The CNIO OncoChip is a cDNA microarray that has been specially designed for looking at genes involved in cancer and includes a core of 2489 cancerrelevant genes in addition to genes involved in drug-response, tissue-specific and control genes. There are a total of 6386 genes represented by 7237 clones (Tracey et al., 2002) . Slides were scanned for Cy3 and Cy5 fluorescence using Scanarray 5000 XL (GSI Lumonics Kanata, Ontario, Canada) and quantified using the GenePix Pro 4.0 program (Axon instruments Inc., Union City, CA, USA). Hybridizations of the human universal reference total RNA from Stratagene (Cy3) against RNA from the different tumors (Cy5) were performed in duplicate using different target preparations.
Data analysis and normalization
Fluorescence intensity from each array element was subtracted from the local background. To normalize the data, the Cy5/ Cy3 ratios were global median normalized. Substandard spots were manually flagged and discarded from further analysis. The Cy5/Cy3 ratios of the duplicated spots in the array were averaged. All ratio values were semilog transformed (base 2). Inconsistent duplicates were discarded whereas uniform duplicated spots were averaged. Gene profiles with less than 70% of available data were excluded from further analysis.
This process yielded 4503 transcripts that were suitable for bioinformatic analysis.
Bioinformatic analysis
The SOTA clustering program (http://bioinfo.cnio.es/cgi-bin/ tools/clustering/sotarray) was used for hierarchical clustering analysis and the GeneCluster/Treeview program was used to view gene expression (Herrero et al., 2001) . To identify the genes that are important for distinguishing subgroups defined by the presence of LKB1 mutations, we carried out an ANOVA test with 50 000 random permutations for P-value computation. Genes with unadjusted Po0.01 were considered the best candidates for identifying differential expression among subgroups. These procedures are implemented in http://bioinfo.cnio.es/cgi-bin/tools/multest/multest.cgi.
FRAP1/mTOR immunohistochemistry
Immunohistochemical staining of FRAP1/mTOR was performed on 5-mm sections from paraffin-embedded tumors. Phospho-mTOR (Ser2448) polyclonal antibody (Cell Signaling, Technology, Berkeley, MA, USA) was diluted at 1 : 50 and after incubation for 60 min at room temperature, immunodetection was performed with EnVision-HRP (DAKO, Copenhagen, Denmark) and peroxidase activity was developed using 3,3-diaminobenzidene (DAB) chromogen as substrate. Sections were counterstained with hematoxylin. A positive control was included with each batch of staining to ensure consistency between consecutive runs.
Quantitative RT-PCR for MEIS2 and AMPD3
To validate the differences in gene expression, we used commercially available Assay-on Demand probe-primer sets (Applied Biosystem, Foster City, CA, USA) to perform realtime quantitative PCR analysis (Taqman Technology) on the MEIS2 and AMPD3 transcripts. Briefly, 1 mg of RNA was reverse transcribed (Reverse Transcription System, Promega, WI, USA) using a random hexamer primer. For Taqman PCR assay, cDNA from 20 ng of total RNA was used to measure gene expression with an ABI Prism 7700 sequence detection system and the reagent TaqMan Universal PCR Master Mix (Applied Biosystems). Target cDNAs were amplified in duplicate using the following cycling conditions: 10 min at 951C and then 40 cycles of amplification (951C for 30 s and 601C for 30 s). The TBP (Human TBP Pre-Developed Taqman Assay Reagents, Applied Biosystems) was used to normalize variations in the input cDNA. The threshold cycle (Ct) was determined and the relative gene expression was calculated as follows: fold change ¼ 2
ÀD(DCt)
, where DCt ¼ Ct target ÀCt TBP (cycle difference) and D(DCt) ¼ Ct LKB1-mutant ÀCt LKB1-wild type .
